MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
Marietta, Ga. – MiMedx Group, Inc. (NASDAQ: MDXG) has announced that shareholders must pre-register by 9:00 a.m. Eastern Time on June 6, 2022, to attend its 2022 Annual Meeting of Shareholders, scheduled for June 7, 2022, at 9:00 a.m. Eastern Time. The meeting will be virtual, allowing shareholders of record as of April 11, 2022, to vote. More details and registration instructions are available at www.votemimedx.com. MiMedx specializes in placental biologics for healthcare, focusing on non-healing wounds and musculoskeletal conditions.
MiMedx Group, Inc. (NASDAQ: MDXG) urges shareholders to support its independent directors in the upcoming vote, addressing misrepresentations by Prescience Point. The company emphasizes its strategic focus on long-term shareholder value, highlighting executive compensation aligned with performance and the significant role of EW Healthcare as a major shareholder. MIMEDX details its advancements in R&D and manufacturing, as well as the successful handling of clinical trial challenges. The 2022 Annual Meeting is set for June 7, 2022, where shareholders can vote via the WHITE proxy card.
MiMedx Group, Inc. (MDXG) has urged shareholders to vote in favor of its nominated directors, James L. Bierman and Phyllis Gardner, during the upcoming 2022 Annual Meeting scheduled for June 7, 2022. The Board emphasizes the significant transformation the company has undergone, overcoming financial challenges and restructuring its management team. New compensation programs have been introduced to align with growth objectives. The letter from Board Chair Dr. M. Kathleen Behrens highlights the company's progress and encourages shareholder participation in the voting process to ensure continued growth.
Prescience Point Capital Management, owning 6.7% of MiMedx Group's stock (MDXG), announced it will WITHHOLD votes against directors Phyllis Gardner and James Bierman during the June 7, 2022, annual meeting. The firm criticized the board for mismanagement, highlighting a 60% drop in share price due to failed clinical trials caused by expired products. Moreover, Prescience Point opposes executive compensation, alleging self-serving actions benefiting the board and EW Healthcare Partners over shareholders. They urged management to buy shares to align with shareholders' interests.
Mimedx Group, Inc. (MDXG) has secured a $4.6 million award to evaluate the PURION processed Dehydrated Human Amnion Chorion Membrane (DHACM) for treating combat wounds and burns. Sponsored by the Medical Technology Enterprise Consortium (MTEC) and the U.S. Army, the funding aims to improve outcomes for military personnel facing acute injuries. Clinical trials will be led by the University of Arizona and University of Miami, focusing on the safety and efficacy of DHACM. This initiative underscores a commitment to addressing critical medical needs in military settings.
MiMedx Group, Inc. (NASDAQ: MDXG) announced decisive actions aimed at stabilizing its operations and fostering growth. The company filed an investor presentation for its 2022 Annual Meeting on June 7, 2022, emphasizing a strategy for long-term value creation. MiMedx reported its third consecutive quarter of double-digit growth in Advanced Wound Care & Surgical Recovery products. The Board of Directors has been entirely reconstituted since 2019, implementing 70 corporate governance reforms. Shareholders are encouraged to vote for director nominees on the WHITE proxy card.
Prescience Point Capital Management, owning 6.7% of MiMedx Group (MDXG), expressed disappointment over the Board's disinformation tactics regarding shareholder discontent. Ahead of the June 7, 2022, annual meeting, Prescience Point claims multiple shareholders share concerns about management's actions and executive compensation. They intend to withhold votes against Board members Phyllis Gardner and James Bierman, criticizing the Board's governance and executive stock awards while calling for transparency from the management about shareholder feedback.
MiMedx Group, Inc. (NASDAQ: MDXG) has urged shareholders to vote in favor of its director nominees, James L. Bierman and Phyllis Gardner, during the upcoming Annual Meeting on June 7, 2022. The company highlights its successful execution of a transformation strategy under CEO Tim Wright, overcoming past litigation and accounting issues. MiMedx recorded its third consecutive quarter of double-digit revenue growth and is poised to advance its Knee Osteoarthritis clinical trial program, which has significant revenue potential. The Board emphasizes ongoing governance reforms and a commitment to enhancing shareholder value.
MIMEDX Group, Inc. (NASDAQ: MDXG) urges shareholders to vote "FOR" directors Dr. Phyllis Gardner and James L. Bierman against accusations from Prescience Point Capital Management. The company highlights its improved governance and ongoing transformation since June 2019, reporting three consecutive quarters of double-digit growth. MIMEDX emphasizes a long-term strategy focusing on sustainable growth, while expressing concerns about Prescience Point's potential short-term motivations and history of destabilizing efforts. The Annual Meeting of Shareholders is scheduled for June 7, 2022.
Prescience Point Capital Management, owning approximately 6.7% of MiMedx Group's stock (MDXG), intends to WITHHOLD votes against Directors Phyllis Gardner and James Bierman at the June 7, 2022, Annual Meeting. The firm criticizes the Board for poor governance, excessive executive compensation, and mismanaged clinical trials that caused a 60% share price drop. Prescience believes MDXG has potential in regenerative medicine, citing promising results for its Amniofix product, but emphasizes the need for accountability and better communication from management to enhance shareholder value.